Diverticular bleeding complicating dual antiplatelet therapy after drug-eluting stent implantation
نویسندگان
چکیده
Acute lower gastrointestinal bleeding is defined as a bleeding situation in which blood loss has been occurring for less than 3 days resulting in haemodynamic instability, anaemia, or the need for blood transfusion. Diverticula and angiectasias are the most frequent sources of bleeding. Malignancy, inflammatory bowel disease, non-steroidal anti-inflammatory drugs, infectious colitis, ischaemia, anorectal disorders, postpolypectomy bleeding, and HIV-related problems are less frequent causes. We describe a case of a female patient aged 87 admitted to hospital because of severe intestinal bleeding. The patient was on dual antiplatelet therapy after drug-eluting stent implantation. After red blood cell and fresh frozen plasma infusion, haemostatic drug treatment as well as withdrawal of antiplatelet agents, the patient’s condition improved and became stable. Colonoscopy was then performed and residual bleeding from diverticula was revealed. Since the patient was free from symptoms and signs of recurrent bleeding, dual antiplatelet therapy was restarted without further complications.
منابع مشابه
Dual Antiplatelet Therapy for 6 Months vs 12 Months After New-generation Drug-eluting Stent Implantation: Matched Analysis of ESTROFA-DAPT and ESTROFA-2.
INTRODUCTION AND OBJECTIVES The recommendation for dual antiplatelet therapy following drug-eluting stent implantation ranges from 6 months to 12 months or beyond. Recent trials have suggested the safety of a 6-month dual antiplatelet therapy regimen, yet certain caveats to these studies limit the applicability of this shorter duration dual antiplatelet therapy strategy in real world settings. ...
متن کاملInterventional Cardiology Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting A Randomized Multicenter Trial
Background—The optimal duration of dual-antiplatelet therapy and the risk-benefit ratio for long-term dual-antiplatelet therapy after coronary stenting remain poorly defined. We evaluated the impact of up to 6 versus 24 months of dual-antiplatelet therapy in a broad all-comers patient population receiving a balanced proportion of Food and Drug Administration–approved drug-eluting or bare-metal ...
متن کاملDual antiplatelet therapy after drug-eluting stents--how long to treat?
The rationale behind dual antiplatelet therapy after successful stenting is based upon two indications. First, the stented segment requires protection from stent thrombosis that occurs as a result of inflammation during healing. Second, the areas inside and outside the stented section require protection from the development of progressive atherosclerosis and plaque rupture. The first of these t...
متن کاملTriple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry).
BACKGROUND Cilostazol has reduced restenosis and repeat intervention after drug-eluting stent (DES) implantation. However, there is little data regarding impact of cilostazol on cardiac events after DES implantation. Therefore, we assessed the long-term efficacy and safety of cilostazol in patients undergoing successful DES implantation. METHODS The patients (n = 3,099) undergoing successful ...
متن کاملEfficacy and safety of 12 versus 48 months of dual antiplatelet therapy after implantation of a drug-eluting stent: the OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial: study protocol for a randomized controlled trial
BACKGROUND Dual antiplatelet therapy with aspirin and thienopyridine is required after placement of coronary drug-eluting stents (DES) to prevent thrombotic complications. Current clinical guidelines recommend at least 6 to 12 months of treatment after a DES implantation, but it may be beneficial to apply dual antiplatelet therapy for a longer duration. METHODS/DESIGN The optimal dual antipla...
متن کامل